Related Experiment Video
Updated: Feb 9, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Repurposing auranofin as an intestinal decolonizing agent for vancomycin-resistant enterococci
Ahmed AbdelKhalek1, Nader S Abutaleb1, Khalifa A Elmagarmid1
1Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, IN, 47907, USA.
Abstract:
Multidrug-resistant enterococcal pathogens, especially vancomycin-resistant enterococci (VRE), are among the pathogens that require new antibiotic innovation. The colonization of the gut represents a major pathway by which VRE can cause infection and spread to other patients. In the current study, auranofin (FDA-approved rheumatoid arthritis drug) is evaluated for its potential use as a decolonizing agent for VRE. Auranofin was found to exert potent antimicrobial activity against a wide range of enterococcal clinical isolates with a minimum inhibitory concentration of 1 μg/mL. No resistant mutants could be developed against auranofin over the course of 14 passages. Auranofin was also found to exert potent anti-biofilm activity against VRE. Auranofin was superior to linezolid, the drug of choice for VRE infection treatment, in the in vivo mouse model. Auranofin significantly reduced the VRE burden in feces, cecum, and ileum contents after 8 days of treatment. Accordingly, this study provides valuable evidence that auranofin has significant promise as a novel gastrointestinal decolonizing agent for VRE.
Insights
Auranofin, an arthritis drug, shows promise in eliminating vancomycin-resistant enterococci (VRE) gut colonization. It effectively reduced VRE in mice, offering a new strategy against these dangerous superbugs.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Multidrug-resistant enterococci, particularly vancomycin-resistant enterococci (VRE), pose a significant threat requiring novel therapeutic strategies.
- Gut colonization by VRE is a primary route for infection and patient-to-patient transmission.
Purpose of the Study:
- To evaluate auranofin, an FDA-approved drug for rheumatoid arthritis, as a potential gastrointestinal decolonizing agent for VRE.
Main Methods:
- Assessed auranofin's antimicrobial and anti-biofilm activity against diverse enterococcal isolates.
- Investigated the development of resistance through serial passage.
- Evaluated auranofin's efficacy in an in vivo mouse model compared to linezolid.
Main Results:
- Auranofin demonstrated potent antimicrobial activity against VRE with a minimum inhibitory concentration of 1 μg/mL.
- No resistant mutants were observed after 14 passages.
- Auranofin significantly reduced VRE burden in murine feces, cecum, and ileum, outperforming linezolid in vivo.
Conclusions:
- Auranofin exhibits significant potential as a novel gastrointestinal decolonizing agent for VRE.
- Its efficacy in reducing VRE colonization and burden suggests a promising therapeutic application.
Related Concept Videos
Anatomy of the Intestines
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...
Resistivity
Resistance
Small Intestine
The small intestine is divided into three main sections - the duodenum, jejunum, and ileum. The duodenum, approximately 25 cm long, is nearest the stomach. It acts as a 'mixing bowl,' where chyme (partially digested food) blends with digestive enzymes from the pancreas and liver. The duodenum's unique...
Large Intestine
The ileocecal sphincter, a mucous membrane fold, guards the opening from the ileum to the large intestine. This valve permits material from the small intestine to pass into the large intestine. Attached to the ileocecal valve is the cecum. This small pouch, approximately 6 cm long, has a twisted, coiled tube known as...
Subviral Agents

